Dasatinib Added to Chemotherapy for Newly Diagnosed Philadelphia Chromosome Positive Leukemia (ALL)

Clinical Trial

Offered by: Nemours Children's
Locations: Delaware Valley

Trial Name

A Phase 2 Multicenter Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

What is the trial about?

To look at the survival rate when a drug called dasatinib is added to standard chemotherapy.

Who can participate?

Age > 1 year and < 18

What is involved?

Length of study is approximately 7 years. Tests and procedures to be done include: Review of medical history; Complete physical exam; Assessment of performance status; Chest X-ray; ECG; ECHO); Collection of blood and urine samples; Spinal tap; DXA; minimal residual disease test; pregnancy test.

Contact Nemours Children's Clinical Trials

Trial Name: A Phase 2 Multicenter Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

COG#: AALL1122

Is a Clinical Trial Right for Your Child?

Learn more about clinical trials and get answers to questions you might have.

Two researchers in a lab wearing coats and gloves, one looks into a microscope.